Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03625648 · ClinicalTrials.gov registry record · Phase 4
Pentoxifylline in Diabetic Kidney Disease
A Phase 4 study of Diabetic Kidney Disease, sponsored by VA Office of Research and Development.
- Active
- Registry status
- Phase 4
- Development phase
- 2,376
- Enrollment target
- 20
- Study locations
NCT03625648 is a Phase 4 study of Diabetic Kidney Disease that is active but no longer recruiting, run by VA Office of Research and Development. The registered enrollment target is 2,376 participants, below the 5,086-participant average among 23 other Diabetic Kidney Disease trials with a reported enrollment target (53% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT03625648, a Phase 4 study of Diabetic Kidney Disease, is active but no longer recruiting, sponsored by VA Office of Research and Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 2,376 participants
- Enrollment target
- 20
- Study locations
Study Summary
Pentoxifylline (PTX) is a medication that has been on the market since 1984 for use in disease in the blood vessels of the legs. There is some preliminary information that it may protect the kidneys from damage due to diabetes and other diseases. "Pentoxifylline in Diabetic Kidney Disease" is a study to bee conducted in 40 VA hospitals across the nation to determine definitively whether or not PTX can prevent worsening of kidney disease and delay death in patients with diabetic kidney disease.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pentoxifylline
Study Locations (20)
California
- VA Loma Linda Healthcare System, Loma Linda, CA - Loma Linda
- VA Long Beach Healthcare System, Long Beach, CA - Long Beach
- VA Palo Alto Health Care System, Palo Alto, CA - Palo Alto
Florida
- Bay Pines VA Healthcare System, Pay Pines, FL - Bay Pines
- North Florida/South Georgia Veterans Health System, Gainesville, FL - Gainesville
- James A. Haley Veterans' Hospital, Tampa, FL - Tampa
Missouri
- Harry S. Truman Memorial, Columbia, MO - Columbia
- Kansas City VA Medical Center, Kansas City, MO - Kansas City
- St. Louis VA Medical Center John Cochran Division, St. Louis, MO - St Louis
Arizona
- Phoenix VA Health Care System, Phoenix, AZ - Phoenix
Arkansas
- Central Arkansas Veterans Healthcare System, Little Rock, AR - Little Rock
Colorado
- Rocky Mountain Regional VA Medical Center, Aurora, CO - Aurora
Georgia
- Atlanta VA Medical and Rehab Center, Decatur, GA - Decatur
Illinois
- Edward Hines Jr. VA Hospital, Hines, IL - Hines
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,376 participants |
| Start Date | 2019-11-18 |
| Est. Completion | 2030-07-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03625648
The ClinicalTrials.gov registry entry for NCT03625648 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 2,376 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,086-participant average among 23 other Diabetic Kidney Disease trials with a reported enrollment target (53% lower). The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Kidney Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03625648 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, Missouri.
Frequently Asked Questions
What is clinical trial NCT03625648 about?
NCT03625648 is a clinical study titled "Pentoxifylline in Diabetic Kidney Disease". Pentoxifylline (PTX) is a medication that has been on the market since 1984 for use in disease in the blood vessels of the legs. There is some preliminary information that it may protect the kidneys from damage due to diabetes and other diseases. "Pentoxifylline in Diabetic Kidney Disease" is a stud...
What is the current status of trial NCT03625648?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 2,376 participants. The study started on 2019-11-18. Estimated completion is 2030-07-08.
What conditions does trial NCT03625648 study?
This clinical trial studies the following conditions: Diabetic Kidney Disease.
What interventions are being tested in trial NCT03625648?
The interventions under investigation include: Placebo (DRUG), Pentoxifylline (DRUG).
Who is sponsoring clinical trial NCT03625648?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03625648 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mechanism of SGLT2 Inhibition in the Kidney
RECRUITING · Phase 4
-
Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes
COMPLETED · Phase 4
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
-
Family Investigation of Nephropathy and Diabetes (F.I.N.D.)
RECRUITING
-
Formoterol in Diabetes
RECRUITING · Phase 2
-
Dosimetry of Tc-99m-Tilmanocept
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.